More than 50 bipartisan lawmakers are urging the Trump administration's Centers for Medicare & Medicaid Services (CMS) to remove a proposed policy regarding fixed-dose combination drugs from its final rule implementing Medicare’s Drug Price Negotiation Program. Signed into law in 2022 under President Biden, this program aims to negotiate drug prices. The lawmakers argue that the proposal could hasten price negotiations for improved versions of existing medications, potentially discouraging pharmaceutical companies from developing these advancements and impacting patient access, especially in rural areas.
Written locally by qwen2.5:14b on 2026-09-29,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
A bipartisan group of over 50 lawmakers is urging the Trump administration's Centers for Medicare & Medicaid Services (CMS) Administrator, Dr. Mehmet Oz, not to finalize a proposed Medicare policy tied to the Biden-era Inflation Reduction Act. The lawmakers submitted an official letter on September 21, arguing that the policy could discourage the development of improved cancer treatments. Specifically, they are concerned about CMS's proposal for fixed-dose combination policies under Medicare’s Drug Price Negotiation Program, which was established by the Inflation Reduction Act in 2022. The lawmakers claim this proposal would cause newer versions of existing drugs to face Medicare price negotiations sooner after FDA approval, potentially reducing drugmakers' incentives to create better treatments.
Written for “Medicare Drug Pricing Law” on 2026-10-05,
grounded in this article and the 0 other(s) covering the same event.
A bipartisan group of more than 50 lawmakers is urging the Trump administration not to finalize a proposed Medicare policy tied to the Biden-era drug price negotiation program, arguing it could discourage development of improved cancer treatments.
uncertain
it → urge → treatments
In a Sept. 21 letter obtained by Fox News Digital, the lawmakers called on Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz to remove the agency's proposed fixed-dose combination policy from its final rule implementing Medicare's Drug Price Negotiation Program.
asserted
lawmakers → obtain → Program
The Medicare Drug Price Negotiation Program was created under the Inflation Reduction Act, which former President Joe Biden signed into law in 2022.
asserted
Biden → create → 2022
The Trump administration proposed the policy in June as part of implementing that program.
asserted
administration → propose → program
At the center of the dispute is how Medicare would treat newer versions of existing drugs for price negotiation purposes.
asserted
treat → treat → purposes
The lawmakers argue the proposal would cause some improved treatments to face Medicare price negotiations much sooner after receiving Food and Drug Administration (FDA) approval.
asserted
treatments → argue → approval
They say that would reduce incentives for drugmakers to develop better versions of existing medicines.
asserted
drugmakers → say → medicines
"If finalized, the proposed fixed-dose combination policy would subject these advancements to negotiation almost immediately after FDA approval, harming patient access as well as incentives to develop these improved therapies," the lawmakers wrote.
asserted
lawmakers → finalize → therapies
CMS, meanwhile, said the proposal is designed to prevent drugmakers from avoiding or delaying negotiated Medicare prices by making only limited changes to existing drugs and introducing them as new products.
asserted
proposal → say → products
The lawmakers pointed to advances in cancer immunotherapy that allow some patients to receive a quick injection instead of spending hours receiving an intravenous infusion.
asserted
patients → point → infusion
They said those improvements can make treatment faster, easier and more accessible, particularly for patients in rural areas.
asserted
treatment → say → areas
"Patients fighting cancer deserve access to the most advanced new therapies, and if CMS finalizes this proposal, those advances are less likely to reach those who need it the most," the letter states.
asserted
letter → fight → it
The lawmakers also argued the FDA already evaluates the therapies as separate medicines, requiring separate clinical trials and approvals.
asserted
FDA → argue → trials
They said CMS should treat those therapies as separate medicines under the Medicare drug price negotiation program.
asserted
CMS → say → program
The lawmakers also argued that CMS actuaries "have not been able to show this policy would produce meaningful savings for taxpayers."
"We strongly urge CMS to withdraw the fixed-dose combination proposal from the final rule," the letter states.
asserted
letter → argue → rule
The patients we represent need policies that expand access to lifesaving care and reward medical progress and innovation in the treatment of deadly diseases."
asserted
that → represent → diseases
The letter was signed by more than 50 lawmakers from both parties, including Reps. John Joyce, R-Pa., Darin LaHood, R-Ill., Mike Kennedy, R-Utah, Tim Moore, R-N.C., Jim Costa, D-Calif., Donald Davis, D-N.C., and more.
asserted
letter → sign → Joyce
CMS could not immediately be reached by Fox News Digital for comment.
uncertain
CMS → reach → comment
The Aporia
